Reversal of Direct Oral Anticoagulants: Meeting a Need & Filling a Gap
Main Article Content
Abstract
Presently, three reversal strategies are available to reverse the anticoagulant activity of the direct oral anticoagulants, each with various limitations or drawbacks. A new reversal agent that addresses some of these limitations or gaps in therapy is in advanced clinical trials. Ciraparantag is a small molecule specifically designed to bind non-covalently by charge-charge interaction to unfractionated heparin and low molecular weight heparin. It shows similar binding characteristics to the direct oral anticoagulants with no off-target binding of selected proteins or commonly used drugs demonstrated to date. Ciraparantag reaches maximum concentration within minutes following intravenous administration with a half-life of 12 – 19 minutes. It is primarily hydrolyzed by serum peptidases into two metabolites, neither of which has substantial activity. Ciraparantag and its metabolites are recovered almost entirely in the urine. In animal models of bleeding a single intravenous dose of ciraparantag given at peak concentrations of an anticoagulant significantly reduces blood loss. In Phase 1/2 clinical trials, ciraparantag restores coagulation in direct oral anticoagulant-treated healthy volunteers with in minutes with a sustained effect over 24 hours. The drug is well tolerated with minor side effects, the most common of which is a flush or sensation of warmth after administration. As a phase 3 trial is in preparation to clinically prove its effectiveness, ciraparantag appears to address many of the short-comings of current reversal strategies.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512orig1s000toc.cfm (accessed February 27, 2023).
3. https://www.drugs.com/history/eliquis.html (accessed February 27, 2023)
4. https://www.drugs.com/history/xarelto.html (accessed February 27, 2023)
5. https://www.drugs.com/history/savaysa.html (accessed February 27, 2023)
6. https://www.drugs.com/history/bevyxxa.html (accessed February 27, 2023)
7. Foerch C, Lo EH, van Leyen K, Lauer A, Schaefer JH. Intracerebral hemorrhage formation under direct oral anticoagulants. Clinical and translational evidence. Stroke 2019;50:1034-1042.
8. Pfeilschifter W, Lindhoff-Last E, Alhashim A , Zydek B, Lindau S, Konstantinides S, Grottke O, Nowak-Goettl U, von Heymann C, Birschmann I, Beyer-Westendorf J, Meybohm P, Greinacher A, Herrmann E. Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: Results of the RADOA-registry. Neurol Res Pract. 2022;4:16.
9. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124(15):2450-8
10. Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014. J A M A. 2016;316(20):2115-25.
11. Lindhoff-Last E. Direct oral anticoagulants (DOAC) – Management of emergency situations. Hamostaseologie 2017;37:257-266.
12. Ansell J. Reversal agents for the direct oral anticoagulants. Hematol Oncol Clin N Am (2016);30:1085–1098.
13. Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med 2017;377:431-441.
14. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nature Med 2013;19:446-451.
15. Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019;380:1326-35
16. Siddiqui F, Tafur A, Ramaciotti LS, et al. Reversal of factor Xa inhibitors by andexanet alfa may increase thrombogenesis compared to pretreatment values. Clin Appl Thromb/Hemost 2019;25:1-7.
17. Milioglou I, Farmakis I, Neudeker M, et al. Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis. J Thromb Thrombolys 2021;52:1137-1150.
18. Chaudhary R, Singh A, Chaudhary R, et al. Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage. A systematic review and meta-analysis. JAMA Network Open 2022;5(11):e2240145. Doi:10.1001/jamanetworkopen.2022.40145.
19. Go AS, Leong TK, Sung SH. Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding. J Thromb Thrombolys 2022;54:470-479.
20. Makhoul T, Kelly G, Kersten B, et al. Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4F-PCC) for oral anticoagulation reversal. Thromb Res 2020;194:158-164.
21. Ansell J, Laulicht BE, Bakhru SH, Burnett A, Jiang X, Chen L, Baker C, Villano S, Steiner S. Ciraparantag, an anticoagulant reversal drug: Mechanism of action, pharmacokinetics and reversal of anticoagulants. Blood 2020;137:115–125
22. Bern BJ, Pecora R. Dynamic Light Scattering: With Applications to Chemistry, Biology and Physics. Mineola, NY: Dover Publications; 2000
23. Ansell J, Zappe S, Jiang X, et al. A Novel Whole Blood Point-of-Care Coagulometer to Measure the Effect of Direct Oral Anticoagulants and Heparins. Semin Thromb Hemost. 2019;45(3):259-263.
24. Bakhru S, Jiang X, Chen L, et al Analytical validation of a novel whole blood coagulometer for NOAC testing [abstract]. Res Pract Thromb Haemost. 2020;4(suppl 1). Abstract PB0638.
25. https://www.biospace.com/article/releases/perosphere-technologies-announces-ce-ivd-marking-of-the-perosphere-technologies-poc-coagulometer-system-for-doac-and-heparin-testing (accessed March 18, 2023)
26. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso MA, Brown K, Dishy V, Lanz JH, Mercuri MF, Noveck RJ, Costin JC. Single Dose Ciraparantag Safely and Completely Reverses Anticoagulant Effects of Edoxaban. Thromb Haemost 2017;117(2): 238-245.
27. Ansell JE, Laulicht BE, Bakhru SH, Hoffman M, Steiner SS, Costin JC. Ciraparantag Safely and Completely Reverses the Anticoagulant Effects of Low Molecular Weight Heparin. Thromb Res 2016; 146:113–118.
28. Ansell J, Bakhru S, Laulicht BE, Tracey G, Villano S, Freedman D. Ciraparantag Reverses the Anticoagulant Activity of Apixaban and Rivaroxaban in Healthy Elderly Subjects. European Heart J 2021;43:985-992; DOI10.1093/eurhearti/ehab637
29. Gage T. Reply to “Is anticoagulation reversal needed/warranted with latest data?” J Thrombo Haemost 2020;18:3115-3116.
30. Eerenberg E S, Levi M, Buller HR. Contra: “Antidotes for novel anticoagulants?” Do we really need them. Thrombo Haemost 2012;108:623-624